Background on CSL's Pandemic H1N1 vaccine

There is only one country in the southern hemisphere able to manufacture its own pandemic influenza vaccine.

Download
null

Panvax^® H1N1 Consumer Medicine Information

CSL, Australia’s leading biopharmaceutical company, is the only commercial manufacturer of influenza vaccines in the Southern Hemisphere. CSL was contracted by the Australian Government to supply 21 million doses of pandemic H1N1 vaccine.

CSL has manufactured a pandemic H1N1 influenza vaccine called Panvax^®H1N1 which uses the proven technology that has enabled us to provide Australia with seasonal flu vaccines over the last 40 years. This technology is also used by the majority of influenza vaccine manufacturers around the world. The process used to manufacture Panvax^®H1N1 vaccine is essentially the same as the process used to manufacture influenza vaccines used to prevent seasonal flu.

To facilitate the distribution and supply of a large number of doses, the vaccine will be supplied primarily in multi-dose vials. It is a requirement that multi-dose vials contain a preservative to maintain sterility. Flu vaccines are routinely supplied in preservative-containing multi-dose vials in other countries eg the United States.

Further information on Panvax^®H1N1 can be found in the Questions and Answers on this website, or by ringing CSL's Medical Information line on 1800 024 204.